Withdrawn application: Lumevoq, lenadogene nolparvovec, Date of withdrawal: 20/04/2023, Initial authorisation

Guidance to applicants/marketing authorisation holders on oral explanations at European Medicines Agency

Human medicines European public assessment report (EPAR): Plerixafor Accord, plerixafor, Multiple Myeloma;Hematopoietic Stem Cell Transplantation, Date of authorisation: 16/12/2022, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz Tetra, influenza vaccine (live attenuated, nasal), Influenza, Human, Date of authorisation: 04/12/2013, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Camzyos, mavacamten, Cardiomyopathy, Hypertrophic, Date of authorisation: 26/06/2023, Revision: 1, Status: Authorised

Declaration of interets: Elias Pean

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Influenza, Human, Date of authorisation: 12/12/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Renagel, sevelamer, Renal Dialysis;Hyperphosphatemia, Date of authorisation: 28/01/2000, Revision: 36, Status: Authorised

PRAC meetings in 2025 and 2026

Human medicines European public assessment report (EPAR): Ruconest, conestat alfa, Angioedemas, Hereditary, Date of authorisation: 28/10/2010, Revision: 12, Status: Authorised